IN3 RELATIONSHIP BETWEEN ADHERENCE TO ANTIRETROVIRAL THERAPY AND THE COST-EFFECTIVENESS OF ANTIRETROVIRAL THERAPY  by Habib, MJ et al.
A206 Abstracts
based on the epidemiology of infectious diseases, national guide-
lines, and pricing and reimbursement mechanisms.
IN3
RELATIONSHIP BETWEEN ADHERENCE TO ANTIRETROVIRAL
THERAPY AND THE COST-EFFECTIVENESS OF
ANTIRETROVIRAL THERAPY
Habib MJ1, Lawson K2, Summers KK3, Eakin RT2, Barner J2,
Brown C2, Shepherd MD2
1i3 Innovus, Burlington, ON, Canada, 2University of Texas at Austin,
Austin,TX, USA, 3South Texas Veterans Health Care System, San
Antonio,TX, USA
OBJECTIVE: The nation’s largest single provider of health care
to those infected with Human Immunodeﬁciency Virus (HIV) is
the Department of Veterans Affairs (VA). The clinical effective-
ness of highly active antiretroviral therapy (HAART) depends
considerably on an individual’s ability to adhere closely to
therapy. The objective of this study was to assess the relation-
ship between patient adherence to HAART and the cost-
effectiveness of HAART in antiretroviral-naïve HIV-infected VA
patients. METHODS: The overall design of the study is a hybrid
between an observational study and a decision-analytic model.
Kaplan-Meier survival estimates, calculated from the VA’s labo-
ratory and clinical data, were used to model HIV-disease pro-
gression. Pharmacy-based adherence was calculated using reﬁll
percent adherence obtained from prescription records; individu-
als were categorized as adherent if adherence was equal to or
greater than 95%. Inpatient and outpatient costs were derived
from the VA Health Economics Resource Center estimates. Out-
patient prescription costs were obtained from the VA’s Pharmacy
Beneﬁts Management database. Markov Monte Carlo simula-
tions were conducted to project the cost-effectiveness of adher-
ence to HAART. Costs and quality-adjusted life-years (QALY)
were discounted at 3%. RESULTS: For the ﬁve-year Markov
Monte Carlo simulations, the overall costs of adherent behavior
were lower than those of non-adherent behavior. In addition, the
projected QALYs of adherent behavior were greater than those
of non-adherent behavior; therefore, the cost-effectiveness of
non-adherent behavior was dominated by adherent behavior. 
For the 20-year simulations, the cost-effectiveness of adherent
behavior, compared to non-adherent behavior, was less than
$15,000/QALY. CONCLUSIONS: Medication non-adherence in
chronic conditions is a recognized public health problem. The
association between medication adherence and improved health
outcomes is well documented and the results of this study
provide further evidence of this relationship. In this study, the
marginal costs and effects associated with adherent behavior,
compared to non-adherent behavior, are well below acceptable
willingness-to-pay thresholds.
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OBJECTIVES: SA is the major cause of bacteraemia and a major
cause of morbidity and mortality in haemodialysis (HD) patients.
The objective was to assess the health care costs associated with
SA bacteraemia requiring hospitalisation in HD patients in
Belgium. METHODS: Data on resource utilization associated
with SA bacteremia were retrospectively collected from hospital
ﬁles. Eligible patients were HD patients requiring hospitalization
due to SA in the years 2002–2005. Centres were selected based
on setting (urban-rural) and region (north-south). Direct medical
costs from the payers’ perspective were considered. Costs were
obtained by multiplying the intensity of medical resource con-
sumption in physical units by the direct cost per unit. RESULTS:
43 patients (32 males) were included with a mean age of 71.5
(St.Err 1.78). The majority of patients (55.8%) underwent dial-
ysis via central venous catheters, 44.2% via arteriovenous ﬁstu-
las. The pathogen was methicillin resistant SA (MRSA) in 49.1%
and methicillin sensitive SA (MSSA) in 58.1% of cases. Vascu-
lar access was the suspected source of bacteraemia in 62.8% of
patients. Bacteraemia related complications such as septic arthri-
tis or endocarditis, occurred in 41.9% of patients. Overall mor-
tality (within 90days) was 32.6%, SA bacteremia related
mortality was 23.3%. The mean total cost of SA bacteraemia
treatment was 8971€ (95%CI: 5082–12861). This includes hotel
cost (5945€), inhospital tests and procedures (716€), inpatient
and ambulatory drugs (497€), physician visits (34€) and bacter-
aemia related readmissions (1779€). MRSA patients showed
poorer outcomes, in terms of mortality as well as complications
and also incurred higher costs, 14,163€ versus 6188€ for MSSA
patients. In multivariate regression analysis on log-transformed
costs, signiﬁcant cost drivers were older age and the occurrence
of complications. Complications occurred more frequently in the
more costly MRSA patients. CONCLUSION: SA bacteraemia in
haemodialysis patients is associated with serious complications,
high mortality rates and high health care costs.
METHODS & CONCEPTS II
MC5
HUMANISTIC BURDEN AND HEALTH RESOURCE
UTILIZATION AMONG NEOVASCULAR AGE-RELATED
MACULAR DEGENERATION (AMD) PATIENTS: RESULTS 
FOR GERMANY FROM A MULTI-COUNTRY CROSS-
SECTIONAL STUDY
Zlateva G1, Xu X2, Lenz C3, Pauleikhoff D4
1Pﬁzer Inc, New York, NY, USA, 2Covance Market Access Services,
Gaithersburg, MD, USA, 3Pﬁzer Pharma GmbH, Germany, Karlsruhe,
Germany, 4Augenarztpraxis des St. Franziskus-Hospital, Münster,
Germany
OBJECTIVES: This cross-sectional, observational, case-control
study was undertaken in 4 EU countries and Canada to charac-
terize and quantify the humanistic and economic burden of
illness in AMD patients compared to elderly controls. Data for
Germany are reported herein. METHODS: Of 401 bilateral neo-
vascular AMD patients and 471 elderly non-AMD (control) sub-
jects, 83 AMD patients and 93 controls were recruited in
Germany. Physicians recorded demographic and treatment infor-
mation. Patients completed a telephone survey of the National
Eye Institute Visual Function Questionnaire (NEI-VFQ-25), the
EuroQol (EQ-5D), the Hospital Anxiety and Depression Scale
(HADS), and history of falls, fractures and health resource uti-
lization. The impact of AMD on functioning and health resource
utilization was compared between AMD patients and controls
using chi-square tests, analysis of variance, and multivariate
regression models. RESULTS: The adjusted mean (95% CI) NEI-
VFQ overall scale score was 51.31 (37.72, 64.90) in AMD
patients, which was substantially worse than in controls (96.31
[82.75, 109.87]) after adjusting for better-seeing eye visual
acuity, age, gender, and co-morbid diseases (p < 0.0001). AMD
patients reported signiﬁcantly more depression symptoms than
controls on the HADS scales (adjusted mean depression scores:
6.17 vs. 2.69, p < 0.0001) after adjusting for covariates. AMD
affected patients’ perceptions of their general health signiﬁcantly
more than control subjects measured by the EQ-5D (0.69 vs.
0.79, p = 0.0360). Average annual per patient costs were €12,156
